Polyphron and Cellino Demonstrate Tissue Manufacturing Across Diverse Patient Backgrounds

Study shows computational platform can engineer consistent 3D tissue structures from patient-derived stem cells, overcoming donor variability.

Apr. 7, 2026 at 2:40pm

Got story updates? Submit your updates here. ›

A vibrant, abstract painting featuring sweeping geometric shapes, concentric cellular structures, and precise botanical spirals in muted earth tones, conceptually representing the intricate biological processes involved in engineering consistent human tissues from genetically diverse patient samples.Polyphron's computational platform navigates the complexities of genetic diversity to engineer consistent, high-performing human tissues from patient-derived stem cells.NYC Today

Polyphron, a company building an autonomous tissue foundry, has published results from a collaboration with Cellino showing that Polyphron's platform can manufacture structured human tissue across genetically diverse, patient-derived iPSC lines without having to re-optimize from scratch for each new donor. The study addresses the donor variability problem, a central bottleneck to autologous tissue manufacturing, by demonstrating that this variability is structured and computationally navigable.

Why it matters

Patient-derived stem cells can behave differently depending on the donor's genetic background, making it challenging to develop a fixed manufacturing protocol that works for all patients. Polyphron's results show this variability is not a fundamental barrier to scale, opening the door for more consistent and reproducible autologous tissue engineering.

The details

Cellino manufactured four clonal iPSC lines from demographically diverse donors using its automated optical bioprocess. Polyphron then differentiated all four lines into 3D neural tissue and used its closed-loop optimization platform to engineer a key structural feature to defined tolerances across every genetic background. Gene expression profiling confirmed over 2,000 differentially expressed genes between lines at baseline, yet Polyphron's platform converged on high-performing tissue in all cases. The platform was able to transfer what it learned from well-characterized reference donors to predict optimal manufacturing conditions for newly onboarded lines from a fraction of the data, demonstrating computational cross-donor optimization for 3D tissue structure from sparse data.

  • The study was published on April 7, 2026.

The players

Polyphron

A company building an autonomous tissue foundry for engineering functional human tissues.

Cellino

A company that builds manufacturing infrastructure for personalized regenerative medicine, from iPSC production through tissue and organ replacement.

Matthew Osman

CEO and Co-Founder of Polyphron.

Nabiha Saklayen

CEO and Co-Founder of Cellino.

Got photos? Submit your photos here. ›

What they’re saying

“These results reframe donor variability from an unsolvable manufacturing obstacle into a structured, computational problem. We reduced the optimization burden from hundreds of conditions to tens and delivered tissue that met or exceeded our reference standard across every donor we tested. The unit economics of autologous tissue manufacturing just changed.”

— Matthew Osman, CEO and Co-Founder of Polyphron

“Cellino produces patient-derived cells with industrial consistency, and Polyphron engineers them into reproducible functional tissue. We started this collaboration less than 90 days ago, I have never known a team work so quickly as Polyphron. Together, we are proving that genetic diversity is a programmable variable, not a barrier to scale.”

— Nabiha Saklayen, CEO and Co-Founder of Cellino

What’s next

The two companies plan to expand the collaboration across the coming months.

The takeaway

This study demonstrates a significant breakthrough in overcoming the donor variability challenge in autologous tissue engineering, paving the way for more consistent and scalable manufacturing of personalized human tissues.